Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 21, 2021 5:29pm

242 Views

Post# 33252571

RE:RE:RE:RE:RE:RE:RE:RE:Markets

Exellent - Thanks Markymark.
That makes comparing easier.

So imagine if we could develop a drug that gets to the brain cells and provides the deficient H2S where it's needed ... along with an active ingredient like an off-patent Rivastigmine.

Can't wait to see how we might perform in that arena !

It all takes time but if we're lucky ... well worth the wait.

: )

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024